| Autor: |
guido cavaletti, Bogliun, G., Zincone, A., Marzorati, L., Melzi, P., Frattola, L., Marzola, M., Bonazzi, C., Cantù, M. G., Chiari, S., Galli, A., Bregni, M., Gianni, M. A. |
| Přispěvatelé: |
Cavaletti, G, Bogliun, G, Zincone, A, Marzorati, L, Melzi, P, Frattola, L, Marzola, M, Bonazzi, C, Cantù, M, Chiari, S, Galli, A, Bregni, M, Gianni, M |
| Jazyk: |
angličtina |
| Rok vydání: |
1998 |
| Předmět: |
|
| Zdroj: |
Scopus-Elsevier |
| Popis: |
Background: Hematopoietic toxicity of high-dose carboplatin (HD-CBDCA) chemotherapy can be managed effectively with autologous blood cell support, but no conclusive data are available on its the neuro- and ototoxicity. Patients and methods: We determined the neuro- and ototoxicity of HD-CBDCA in 10 patients affected by advanced ovarian cancer. HD-CBDCA was delivered as 24-hour continous infusion or as 5-day schedules. Each patient underwent an extended clinical and instrumental neurological and otological evaluation before, during and after treatment. Results: After HD-CBDCA only I patient had a clinically-evident peripheral neuropathy, while 3 additional patients had only distal paresthesias. Neurophysiological examination evidenced mild, although diffuse, sensory nerve impairment. Motor nerve impairment war also occasionally observed All the sensory and motor pathological changes had a favorable course during the follow-up period. Ototoxicity was more severe than neurotoxicity and, in one case it was dose-limiting and audiologic impairment tended to remain constant also in the follow-up period. Conclusions: HD-CBDCA treatment can be tolerated by most of the patients, but careful monitoring of neuro- and, especially, ototoxicity should be planned |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
